A FOGSI President's Initiative



TOG-6 ALGORITHMS









PPRECIATION AWA

Dr. Harsh Vardhan,

Minister of Science & Technology, Earth Sciences Environment, Forest & Climate Change, Government of India appreciated TOG conclave and **Dr. Nandita Palshetkar**, President, FOGSI for a unique Science Generating Platform.

CONTENTS

IMMUNIZATION IN PREGNANCY
NAUSEA AND VOMITING IN PREGNANCY
POSTPARTUM CARE AND CONTRACEPTION1
PRETERM LABOUR2

A FOGSI President's Initiative



This is an independent publication owned by Science Integra[®]. The advice, opinion, statements, materials and other information expressed and contained in this book are solely those of the experts in the relevant field. The contents including text, graphics and images of the book are meant for educational and informational purposes only. Although great care has been taken in compiling and checking the information, neither Abbott or Science Integra shall be responsible/liable in any way for the present and/or continued accuracy of the information or for any errors, omissions or inaccuracies in this publications whether arising from negligence or otherwise howsoever, or for any consequences arising therefrom. Opinions expressed do not necessarily reflect the views of Abbott India.

The information in this book is meant only to supplement and not to replace the practice guidelines set by International, National Associations and Government bodies. The author/s, Doctors, sponsor and publisher advise readers to take full responsibility before practicing any of the suggested guidelines described in this book, be sure not to take risks beyond your level of experience, aptitude, training, and comfort level. These of course are only opinions of our experts and not recommendations or guidelines and are only meant to give the readers a systematic flow chart to follow, using your own expertise to make final judgements. Any unauthorized reproduction or distribution of this publication is illegal.







Dear FOGSIANs,

In this era of evidence-based medicine, Gynaecologists often must make decisions where neither evidence nor consensus exists. Fortunately, there is a growing body of evidence to assist in managing various conditions related to Obstetrics & Gynaecology. With the TOG-6 algorithms, the idea is to regularly create evidence and consensus based practical approach to the diagnosis and management of indications, thereby ensuring a higher quality of care to patients.

FOGSI & TOG-6 intends to bring the best talent across the country and get them to discuss, deliberate and create easy point of reference to practice better.

Hope you all will maximize from the TOG-6 algorithms and pass on further for the betterment of the community and the STREE in all. Our sincere gratitude to Abbott India Ltd. for their educational grant for the TOG-6 algorithms.

Best wishes!

Adrile P. Palshetkor

Dr. Nandita Palshetkar MD, FCPS, FICOG President 2019 - Federation of Obstetrics & Gynecological Societies of India (FOGSI)

IMMUNIZATION IN PREGNANCY

FOGSI President

Moderators

Co-ordinators

Panelists

- : Dr. Nandita Palshetkar
 - : Dr. P. K. Shah, Dr. Bipin Pandit
- : Dr. Sheetal Punjabi
- : Dr. Bakul Parekh (Paediatrician), Dr. Komal Chavan, Dr. Sneha Bhuyar, Dr. Elizabeth Jacob, Dr. Sherley Mathen



From left to right: Dr. Sherley Mathen, Dr. Elizabeth Jacob, Dr. Bakul Parekh, Dr. Bipin Pandit, Dr. P. K. Shah, Dr. Komal Chavan, Dr. Sneha Bhuyar, Dr. Sheetal Punjabi

It is rightly said that "Colostrum is the first immunization in an infant's life. With the advancement in science, in both disease causing micro-organisms and in the field of medicine, the unborn baby can be protected in the mother's womb by vaccinating the pregnant woman - a type of cocooning effect. Dr. Bakul Parekh (President - IAP)

10 important points to ponder

- 1. Pregnant women are at an increased risk of severe illness and complications from some vaccine preventable illnesses e.g. influenza (flu).
- 2. Passive immunity by transplacental transfer of antibodies may protect vulnerable neonates.
- 3. When indicated, vaccination can be given anytime during pregnancy to decrease adverse pregnancy outcomes and perinatal outcomes.
- 4. Avoid pregnancy for at least 4 weeks after any vaccination.
- 5. The risk of vaccination during pregnancy is largely theoretical.
- 6. If vaccinated inadvertently during pregnancy with vaccine contraindicated during pregnancy or subject gets pregnant within 4 weeks of taking vaccination, no intervention in the form of MTP is required.
- 7. Avoid preferably in first trimester a vaccine with killed agents eg., cholera, inactivated typhoid, hepatitis B.
- 8. Live viral vaccines are contraindicated during pregnancy e.g. MMR, varicella, yellow fever, typhoid, Japanese encephalitis etc.
- Cocooning: Strategy to vaccinate pregnant women in 3rd trimester or immediate postpartum and all those who are in close contacts of neonates and infants less than 12 months [Parents, grandparents, siblings, all health-care providers] with Tdap IIV to reduce risk of transmission in infant.
- 10. Small pox and yellow fever vaccinations are contraindicated during breastfeeding.

IAP: Indian Academy of Pediatrics; MTP: medical termination of pregnancy; MMR: Measles, mumps, and rubella; Tdap: tetanus, diphtheria, pertussis

Current vaccine recommendations for pregnant women

Vaccine	Type of vaccine	During pregnancy	Atleast one month before pregnancy	Immediate post-partum if not immunized earlier	Remarks
Vaccines recom	mended for all pre	egnant women			
Influenza Inactivated influenza vaccine IIV (QIV / TIV) ^{1,2}	Inactivated viral subunit vaccine	1 Dose at any gestational age preferrably between 27–36 weeks or during flu	YES	YES	Annually 1 dose during flu Practice Cocooning
Tetanus Diphtheria ¹ Pertussis (Tdap/Td) ¹	Tetanus and diphtheria – Inactivated toxoids Acellular pertussis – Inactivated subunit vaccine	1 dose of Tdap during each pregnancy regardless of prior Tdap receipt at any time during pregnancy Preferrably between 27–36 weeks	YES	YES	Practice Cocooning
Tetanus toxoid vaccine (TT) ³	Tetanus inactivated toxoid vaccine	First dose as soon as pregnancy detected. Second dose, 4–6 weeks after first dose WHO - 3 rd dose given after 6 months of second dose. Protects her for 5 years	-	-	If she has received 2 TT in last pregnancy and gets pregnant again within 3 years, only 1 dose of TT

TIV: trivalent inactivated influenza vaccines; QIV: quadrivalent inactivated influenza vaccines; Tdap: tetanus, diphtheria, pertussis; Td: tetanus and diphtheria; WHO: World Health Organization

Vaccines contraindicated during pregnancy

Vaccine	Type of vaccine	During pregnancy			Remarks	
Measles mumps rubella (MMR) ^{1,2}	Live-attenuated viral vaccine	CONTRAINDICATED	-	YES	1 dose immediately postpartum if rubella non-immune or susceptible to Rubella 1–2 doses, lifetime protection	
Varicella vaccine for chickenpox (VAR) ^{1,2}	Live-attenuated viral vaccine	CONTRAINDICATED	_	YES	1 dose, immediately postpartum if varicella non-immune 2 doses, 6–8 weeks apart for lifetime protection	
Influenza (LAV) ¹	Live-attenuated viral vaccine	CONTRAINDICATED	_	-		
Human Papilloma virus vaccine (HPV) ¹	Inactivated viral vaccine	CONTRAINDICATED	YES	YES	If found pregnant after initiating 3 dose series, remainder doses should be given after delivery	
BCG	Live attenuated bacterial vaccine	CONTRAINDICATED	_	-	_	
Polio vaccine - Oral polio vaccine (OPV) - Inactivated polio vaccine	Live attenuated vaccine	NOT RECOMMENDED	-	-	-	
Cholera vaccine		NOT RECOMMENDED	-	-	-	
Hemophilus influenza type B vaccine (Hib)		NOT RECOMMENDED	_	-	-	
Zoster vaccine live (ZVL)	Live attenuated viral vaccine	NOT RECOMMENDED	_	_	-	
BCG: Bacillus Calmette–Guérin						

Vaccines recommended for pregnant women with risk factors/special circumstances

Vaccine	Type of vaccine	During pregnancy			Remarks
Hepatitis A vaccine (Hep A)²	Inactivated whole-cell viral vaccine	2 doses, 6 months apart if risk of infection outweighs theoretical risk of vaccine	YES	YES	2 lifetime doses
Hepatitis B vaccine (Hep B)	Inactivated viral recombinant subunit vaccine	3 doses over 6 months if previously unvaccinated or at high risk of exposure (Multiple sex partners in previous 6 months, treated for any STD, recent or current injection drug abuse, HBsAg positive partner, simply wants protection)		YES	3 lifetime doses
Pneumococcal-13 valent conjugate vaccine (PCV 13) ¹ Pneumococcal 23 valent polysaccharide vaccine (PPSV 23) ²	Inactivated bacterial conjugate vaccine Inactivated bacterial polysachharide vaccine	1 dose if risk factor present eg. diabetes	YES	YES	-
Meningococcal serogroups A,C,W,Y vaccine (Men ACWY) ^{1,2} Meningococcal serogroup B Vaccine (Men B-4c MenB- FHbp) ^{1,2}	Inactivated bacterial polysachharide vaccine Inactivated bacterial polysachharide vaccine	1 dose if risk factor present	YES	YES	-
Yellow fever vaccine ²	Live attenuated viral vaccine	1 dose if travelling to endemic region and risk of infection outweighs theoretical risk of vaccine	-	-	-
Japanese encephalitis vaccine	Live attenuated viral vaccine	1 dose if travelling to endemic region and risk of infection outweighs theoretical risk of vaccine	-	-	-
Typhoid vaccine	Live attenuated bacterial recombinant	NOT RECOMMENDED due to lack of data. In general, live vaccines like Ty21a are contraindicated in pregnancy. Vi polysaccharide vaccine should be given to pregnant women only if clearly needed.	-	_	-
Rabies vaccine ²	Inactivated whole-cell viral vaccine	Post exposure prophylaxis (PEP) consider preexposure prophylaxis if risk of exposure very high e.g. Pets at home	YES IF INDI- CATED	-	-
Anthrax vaccine ²	Inactivated bacterial subunit vaccine	Post Exposure Prophylaxis (PEP)	NO DATA	-	-
Recombinant Zoster vaccine (RZV)	Inactivated viral recombinant subunit vaccine diseases; HBsAg: hepatitis I	NOT RECCOMMENDED	-	YES IF INDICATED	-


Immunization by following a standard protocol can save the lives of many pregnant women and neonates who are vulnerable to such diseases. As the old proverb goes - prevention is better than cure.
- Dr. Bakul Parekh (President - IAP)

References

- 1. Bhatt B, Jindal H, Malik JS, et al. Vaccination for pregnant women: Need to address. Hum Vaccin Immunother. 2014; 10(12):3627-8.
- 2. Swamy GK, Heine RP. Vaccinations for Pregnant Women. Obstet Gynecol. 2015 Jan; 125(1): 212–226.
- 3. WHO recommendation on tetanus toxoid vaccination for pregnant women. 2018. https://extranet.who.int/rhl/topics/ preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/who-recommendation-tetanus-toxoidvaccination-pregnant-women

NAUSEA & VOMITING IN PREGNANCY

- **FOGSI President**
- Moderators
- Panelists
- : Dr. Nandita Palshetkar
 - : Dr. Alpesh Gandhi Dr. Aswath Kumar
 - : Dr. Fessy Louis
 - Dr. Rakhi Singh
 - Dr. Abha Rani Sinha
 - Dr. Niranjan Chavan
 - Dr. Tarini Taneja
 - Dr. Charumati Pekhale



From left to right: Dr. Niranjan Jadhav, Dr. Rakhi Singh, Dr. Aswath Kumar, Dr. Alpesh Gandhi, Dr. Abha Rani Sinha, Dr. Tarini Taneja, Dr. Charumati Pekhale, Dr. Fessy Louis

Introduction

Nausea and vomiting in pregnancy (NVP) is a very common disorder reported in 70%–80% of all pregnant women.¹ The symptoms usually begin 2–4 weeks after fertilization, peaks between 9 and 16 weeks and resolve by 22 weeks gestation. Ten percent of women may continue till delivery. The severe form of NVP is called hyperemesis gravidarum. The pathogenesis remains unclear and is multifactorial. The treatment is challenging and ranges from dietary modifications, medical management to hospitalization.

NVP should only be diagnosed when the onset is in the first trimester of pregnancy. The other causes of nausea and vomiting should be excluded. Hyperemesis gravidarum can be diagnosed when protracted nausea and vomiting are associated with a triad of symptoms: Weight loss of more than 5% of pre-pregnancy weight, dehydration, and electrolyte imbalance.²

Risk factors¹

- Younger nullipara
- Under and overweight women
- Multiple pregnancy
- Molar pregnancy
- Socioeconomic factors marital status, lower education
- Genetics
- History of hyperemesis gravidarum in previous pregnancy and family
- Female fetus

Etiopathogenesis Hormonal stimulation

Human chorionic gonadotropin (hCG): The link between hCG and NVP is based on the temporal relationship between the peak symptoms of NVP and the peak levels of hCG production, both of which occur between 8 and 11 weeks of gestation. Higher urinary and serum hCG levels have been noted in NVP cases compared to asymptomatic woman. The extent of hCG stimulation may be modified by placental conditions that elevate its concentration (e.g., multiple gestation or molar gestation) and by hormone-receptor interactions modifying the effect of the hormone.³

Furthermore, hCG has been shown to be a thyroid stimulator of pregnancy. Several studies have exhibited the correlation between transient hyperthyroidism and NVP. Due to cross reactivity between hCG and the thyroid stimulating hormone (TSH) receptor, thyroid dysfunction has been evaluated as a possible mechanism for NVP and hyperemesis gravidarum development.¹

Estrogen and progesterone: The ovarian hormones, estrogen and progesterone, have been implicated in the pathogenesis of NVP and hyperemesis gravidarum. NVP is more common when estradiol levels are increased and less common when estradiol levels are decreased.³ Estrogen contributes to hyperemesis gravidarum by triggering the production of nitric oxide via nitrogen oxidase synthetase, which in turn relaxes smooth muscle slowing gastric intestinal transit time and gastric emptying. Cigarette smoking is associated with lower levels of hCG and estradiol, thereby lowering the risk of hyperemesis gravidarum in smokers.³

Progesterone in combination with estrogen may also elevate the risk for NVP. Progesterone reduces smooth muscle contractility and may alter gastric emptying, leading to increased nausea and vomiting.¹

Prostaglandin E2 (PGE2) and leptin: The role of placental PGE2 has been implicated in the pathogenesis of NVP due to its effect on gastric smooth muscle. Additionally, hCG has been shown to stimulate placental PGE2 which peaks between 9 and 12 weeks of gestation. A study conducted by North et al. has reported higher maternal serum PGE2 levels during periods of nausea and vomiting in early pregnancy compared to asymptomatic periods.⁴

Serum leptin levels have been found to be significantly higher in patients with hyperemesis gravidarum compared to healthy pregnant controls. Leptin may contribute to hyperemesis gravidarum by increasing hCG secretion by the paracrine action of the placenta or by decreasing appetite and promoting more severe nausea and vomiting.^{5,6}

Immune system dysregulation

Hyperemesis gravidarum has been associated with abnormal regulation of the immune system. The normal shift in pregnancy wherein T-helper cell types move into T-helper cell type 1 is exaggerated in hyperemesis gravidarum resulting in increased release of interleukin (IL)-4 as well as tumor necrosis factor-alpha. Furthermore, elevated levels of IL-6, immunoglobulin G (IgG), IgM, complement levels, and lymphocyte counts have been reported in women with hyperemesis gravidarum.¹

Gastrointestinal motility

Few studies have shown a correlation between alterations in the lower esophageal sphincter (LES) resting pressure/esophageal peristalsis and NVP. Estrogen and progesterone are the triggers of esophageal dysmotility in pregnancy wherein estrogen serves as a primer and progesterone causes LES relaxation.⁷ Higher levels of progesterone in pregnancy has also been linked with changes in gastric motility.

Helicobacter pylori (H. pylori) infection

Infection with *H. pylori* has been considered to play a role in the pathogenesis of hyperemesis gravidarum. In a study conducted by Bagis et al. histologic examination of the mucosal biopsy revealed that 95% of hyperemesis gravidarum patients tested positive for *H. pylori* compared with 50% in the control group.⁸ *H. pylori* may exacerbate hormone-induced changes in the nerve and electric functioning of the stomach thereby increasing the risk for more severe nausea and vomiting.

Psychosocial factors

Previous studies have proposed that NVP may be a psychosomatic illness, in which vomiting represents intrapsychic conflicts. Few studies have speculated that NVP is a manifestation of a woman's subconscious attempt to reject an unwanted or undesired pregnancy.¹

Although there are no definite psychogenic causes of hyperemesis gravidarum, the latter has been linked with psychological disturbances, namely neurotic tendencies, hysteria, rejection of femininity, rejection of pregnancy as well as depression and psychological stress related to poverty and marital conflicts.⁹

History

- Previous history of NVP/hyperemesis gravidarum.
- **History to exclude other causes:** Abdominal pain, urinary symptoms, infection, drug history, chronic *H. pylori* infection.
- Quantify severity using PUQE score: Nausea, vomiting, hypersalivation, spitting, loss of weight, inability to tolerate food and fluids, effect on quality of life.¹⁰

Circle the answer that best suits your situation from the beginning of your pregnancy	Points
1. On an average in a day, for how long do you feel nauseated or sick to your sto	mach?
Not at all	1
≤ 1 hour	2
2 to 3 hour	3
4 to 6 hours	4
>6 hours	5
2. On an average in a day, how many times do you vomit or throw up?	
l did not throw up	1
1 to 2 times	2
3 to 4 times	3
5 to 6 times	4
≥ 7 times	5
3. On an average in a day, how many times do you have retching or dry heaves v bringing anything up?	without
None	1
1 to 2 times	2
3 to 4 times	3
5 to 6 times	4
≥ 7 times	5

Total score: Mild NVP : \leq 6; Moderate NVP: 7–12; Severe NVP: \geq 13

Investigations

Nausea and vomiting in pregnancy Mild

- Urine ketones
- Complete blood count
- Serum electrolytes

Severe

- Complete blood count
- Blood sugars
- Urine ketones
- Serum electrolytes
- Blood urea
- Liver function tests
- Arterial blood gases
- Thyroid function tests
- Ultrasound of obstretics and abdomen

Maternal effect of NVP

- Significant detrimental effect on physical quality-of-life and work.
- Increased risk of preeclampsia.
- Increased feelings of depression, negative impact on employment, household duties, parenting and family relationships.
- Significant maternal morbidity due to dehydration, electrolyte and acid-base imbalance, nutritional deficiency, ketonuria, and loss of more than 5% of body weight.
- May lead to acute kidney injury, liver dysfunction, pneumomediastinum, ruptured esophagus, and Wernicke's encephalopathy.

Fetal effects

- No significant congenital anomalies have been demonstrated.
- Increased incidence of low birth weight, small for gestational age (SGA), and premature infants.

Management

Dietary modifications

- Eat small, frequent meals to avoid gastric distention.
- Avoid foods with strong odors/tastes, spicy food, caffeine.

- Increase protein and decrease high-fat and fried foods.
- Eat dry carbohydrates upon awakening, avoid late dinner.
- Try ginger, raspberry, and peppermint tea.
- Drink plenty of liquids, but only very small quantities at a time, between meals, rather than with meals.
- To take prenatal vitamins for one month before fertilization.


Lifestyle modifications

- Decrease or eliminate cigarette smoking.
- Brushing teeth after eating.
- Avoid lying supine for 2 hours after eating.
- Consider chewable prenatal vitamins.
- Straight posture to decrease stomach compression.
- Avoid mental stress and to keep mind occupied.

First-line treatment – Combination drugs (Doxylamine Succinate 10 mg + Pyridoxine Hydrochloride 10 mg)

- Category A drug.
- In NVP, it is the only approved combination by Central Durgs Standard Control Organisation (CDSCO).
- Delayed release medication.
- Should not be crushed or chewed. Food may affect absorption, so to increase the likelihood of maximum benefit tablets are best taken on an empty stomach.
- The initial starting dose is two tablets at bedtime. If symptoms are relieved, the next day
 this dosing schedule can be maintained. If symptoms persist, the dose can be increased to
 one tablet in the morning and two tablets at bedtime. If adequate relief still isn't obtained,
 the dose can be increased a final time to one tablet in the morning, one in mid-afternoon
 and two at bedtime. Four tablets is the maximum dose that can be taken each day.
- Not recommended in breast feeding women.
- It is recommended by the American College of Obstetricians and Gynecologists (ACOG) and Royal College of Obstetricians & Gynaecologists (RCOG) for treating NVP.

Algorithm: Management of NVP¹¹



Add the following (Only if the symptoms does'nt disappear)

- Dimenhydrinate, 25–50 mg every 4–6 hours, orally as needed (not to exceed 200 mg per day if patient also is taking doxylamine)
- Diphenhydramine, 25–50 mg orally every 4–6 hours
- Prochlorperazine, 25 mg every 12 hours rectally

OR

OR

OR

Promethazine, 12.5–25 mg every 4–6 hours, orally or rectally

Pharmacological therapy

Early treatment of NVP is recommended to prevent the progression to hyperemesis gravidarum. The pharmacological therapies available for the treatment of NVP have been presented in table below.

Agents	Pregnancy category	CDSCO approval in NVP	Comments	
Doxylamine Succinate 10 mg + Pyridoxine Hydrochloride 10 mg	Category A	Approved	 The combination of pyridoxine plus doxylamine is approved by the United States FDA for treatment of NVP in women who do not respond to lifestyle changes Recommended as first-line pharmacotherapy for NVP The pyridoxine-doxylamine combination has been found to be safe and does not cause adverse effects in the fetus 	
 Dopamine antagonists Metoclopramide Phenothiazine medications (Promethazine, Prochlorperazine). Droperidol 	Category B	Not approved	 Side-effects of metoclopramide include dystonia, restlessness, somnolence. In 2009 the FDA added a black box warning to metoclopramide due to the risk of tardive dyskinesia with chronic use Side-effects of promethazine, prochlorperazine include drowsiness, decreased seizure threshold, akathisia Side-effects of droperidol include drowsiness, dizziness, cardiac arrythmias. Droperidol bears a black box warning as it may cause QT prolongation and cardiac dysrhythmias 	
AntihistaminesDiphenhydramineDimenhydrinate	Category B	Not approved	• Side-effects include drowsiness, dizziness, HA, fatigue	
Serotonin 5-hydroxy tryptamine type 3 (5-HT3) receptor antagonists • Ondansetron	Category B	Not approved	 Common adverse effects of ondansetron include headache, drowsiness, fatigue, and constipation Ondansetron can prolong the QT interval, especially in patients with underlying heart problems, hypokalemia, or hypomagnesemia There is insufficient data on fetal safety with ondansetron use A possible association of ondansetron use in the first trimester and cleft palate has been reported, but the data is limited by a small sample size 	
CorticosteroidsMethylprednisolone	Category B	Not approved	 Side-effects include hyperglycemia, possible increased risk of oral facial clefts with first trimester use 	
H2 blockers • Ranitidine	Category B	Not approved	• Side-effects include HA, drowsiness, dizziness, diarrhea or constipation	
Proton pump inhibitorsLansoprazoleEsomeprazole	Category B	Not approved	• Side-effects include HA, nausea, diarrhea, fatigue	
CDSCO: Central Durgs Standard Control Organisation; FDA: Food and Drug Administration; NVP: Nausea and vomiting in pregnancy				

Clinical pharmacology of Doxylamine Succinate + Pyridoxine Hydrochloride

Mechanism of action:

- Doxylamine is a H₁ antihistamine. H₁ receptors are located in nucleus tractus solitarius, chemoreceptor trigger zone (CTZ) and vestibular apparatus which on stimulation promote nausea and vomiting. By blocking H₁ receptors, Doxylamine prevents vomiting.
- Pyridoxine: Vitamin B₆ serves as a co-factor for enzyme glutamate decarboxylase and increases the synthesis of gamma-aminobutyric acid (GABA), which serves as inhibitory neurotransmitter at CTZ.

Pharmacokinetics

The pharmacokinetics of delayed-release doxylamine succinate and pyridoxine hydrochloride has been characterized in healthy non-pregnant adult women.¹²

Absorption

- A single-dose (two tablets) and multiple-dose (four tablets daily), open-label study was conducted to assess the safety and pharmacokinetic profile of delayed-release doxylamine succinate and pyridoxine hydrochloride administered in healthy non-pregnant adult women. Single-doses (two tablets at bedtime) were administered on days 1 and 2. Multiple-doses (one tablet in the morning, one tablet in the afternoon and two tablets at bedtime) were administered on days 3-18.
- Blood samples for pharmacokinetic analysis were collected pre-and post-dose on days 2 and 18 as well as pre-dose prior to bedtime dose only (trough) on days 9, 10, 11, 16, 17, and 18.
- Doxylamine and pyridoxine are absorbed in the gastrointestinal tract, mainly in the jejunum.
- The maximum serum concentration (C_{max}) of doxylamine and pyridoxine are achieved within 7.5 and 5.5 hours, respectively.

Guideline recommendations

Below table showcases the recommendations of various guidelines for the management of NVP and hyperemesis gravidarum.

Guidelii	Guideline recommendations for the treatment of NVP and HG			
Guideline	Recommendations			
American Congress of Obstetricians and Gynecologists ³	 Pyridoxine (vitamin B6) and Doxylamine is recommended as the first- line agents when conservative treatment with dietary and lifestyle changes is unsuccessful¹³ Women with a history of NVP or HG in a prior pregnancy are advised to take a multivitamin at the time of the next conception 			
Royal College of Obstetrics and Gynecology ²	 The combination of doxylamine and pyridoxine is significantly more effective than pyridoxine alone There are safety and efficacy data for first-line antiemetics such as antihistamines (H, receptor antagonists) and phenothiazines and they should be prescribed when required for NVP and HG. Combinations of different drugs should be used in women who do not respond to a single antiemetic Metoclopramide is safe and effective, but because of the risk of extrapyramidal effects it should be used as second-line therapy Data from the Swedish Medical and Birth Register has demonstrated a small increased risk of cardiovascular defects and cardiac septal defects (OR 1.62, 95% CI 1.04–2.14, and risk ratio 2.05, 95% CI 1.19–3.28, respectively) with ondansetron. Owing to these reasons, the use of ondansetron should be limited to patients who are not adequately managed on the aforementioned antiemetics and preferably used after the first trimester of pregnancy¹⁴ Enteral or parenteral treatment should be considered along with a multidisciplinary approach when all other medical therapies have failed 			
Drug Controller General of India (DCGI)	• The formulation of Doxylamine 10 mg and Pyridoxine 10 mg is approved in India for the treatment of NVP			
NVP: Nausea and vomiting of pregnancy; HG: Hyperemesis gravidarum				

Conclusion

- NVP is probably the most common disorder in pregnancy.
- It ranges in spectrum from mild to its pathologic form hyperemesis gravidarum.
- NVP significantly reduce the quality of life of the pregnant woman and has a large economic impact on patients, caregivers and society, yet this disorder is very often underestimated.
- Although the pathogenesis of NVP remains unclear, it is widely accepted that it is likely to be multifactorial.
- Doxylamine Succinate 10 mg + Pyridoxine Hydrochloride 10 mg is recommended by ACOG and RCOG in the management of NVP.
- Treatment with doxylamine-pyridoxine combination has demonstrated a significantly larger improvement in symptoms of nausea and vomiting of pregnancy on PUQE score and its safety has been demonstrated over 2,00,000 pregnant women hence should be considered as first-line treatment.
- Pre-emptive use of the delayed combination of doxylamine-pyridoxine can mitigate symptom severity among women who had experienced severe NVP in the previous pregnancy, hence should be considered in previous history of NVP.

References

- 1. Lee NM, Saha S. Nausea and Vomiting of Pregnancy.Gastroenterol Clin North Am. 2011; 40(2): 309-vii.
- RCOG. The Management of Nausea andVomiting of Pregnancy and Hyperemesis Gravidarum. Green-top Guideline No. 69 June 2016. Available from https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg69hyperemesis.pdf
- 3. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018; 131:e15.
- 4. North RA, Whitehead R, Larkins RG. Stimulation by human chorionic gonadotropin of prostaglandin synthesis by early human placental tissue. J Clin Endocrinol Metab. 1991; 73:60–70.
- 5. Aka N, Atalay S, Sayharman S, et al. Leptin and leptin receptor levels in pregnant women with hyperemesis gravidarum. Aust N Z J Obstet Gynecol. 2006; 46:274–77.
- 6. Demir B, Erel CT, Haberal A. Adjusted leptin level (ALL) is a predictor for hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2006; 124:193–96.
- 7. Richter JE. Review article: The management of heartburn in pregnancy. Aliment Pharmacol Ther.2005; 23:749–57.
- 8. Bagis T, Gumurdulu Y, Kayaselcuk F, et al. Endoscopy in hyperemesis gravidarum and Helicobacter pylori infection. Int J Gynaecol Obstet. 2002;79:105–09.
- 9. Beyazit F, Sahin B. Effect of nausea and vomiting on anxiety and depressionlevels in early pregnancy. Eurasian J Med. 2018; 50(2): 111–15.
- 10. Koren G, Boskovic R, Hard M, Maltepe C, et al. Motherisk-POQE (pregnancy-unique qualification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. American Journal of Obstetrics and Gynecology. 2002; 186: S228-31.
- 11. Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: An updated algorithm. Canadian Family Physician.2007;53 (12): 2109-111.
- 12. Matok I, Clark S, Caritis S, et al. Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. J Clin Pharmacol. 2013;53(3): 334-38.
- 13. Nuangchamnong N, Nieby J. Doxylamine succinate–pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health. 2014;6: 401–09.
- 14. Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol.2014;50:134–37.

POSTPARTUM CARE AND CONTRACEPTION

FOGSI President

Moderators

Panelists

- : Dr. Nandita Palshetkar
- : Dr. Shanta Kumari, Dr. Rajat Mohanty
- : Dr. Rajat Mohanty, Dr. Swarnalatha S, Dr. Basab Mukherjee, Dr. Shobha Gudi, Dr. Mandakini Megh, Dr. Kiran Kurtkoti, Dr. Punit Bhojani, Dr. Rajnikant Contractor, Dr. Radhamani K




From left to right: Dr. Punit Bhojani, Dr. Radhamani K, Dr. Swarnalatha S, Dr. Mandakini Megh, Dr. Basab Mukherjee, Dr. Rajat Mohanty, Dr. Rajnikant Contractor, Dr. Shobha Gudi, Dr. Kiran Kurtkoti

9 major points to ponder


- 1. Holistic care provided to the parturient and the new born after childbirth extending to a period of 6-8 weeks and up to one year.
- 2. Though traditionally done at 6 weeks, the timing of the postpartum visit needs to be individualized and women-centred.
- 3. Appropriate advice on nutrition, breast feeding, exercise, emotional and psychological support should be provided.
- 4. Optimization of pre-existing medical disorders and ongoing medication.
- 5. Prevention, early diagnosis and treatment of immediate and delayed complications and early referral when necessary.
- 6. Discuss birth control methods for spacing/limiting family size. Ideally counselling for immediate postpartum contraception should start in the antenatal period.
- 7. Immunization and vaccination for the mother and neonate.
- 8. Lifestyle management, specially abdominal exercises and appropriate dietary modifications.
- 9. Calcium supplementation and hematinics to be considered.

Algorithm – PPCC in all breastfeeding



CuIUCD: copperIUCD; LAM: lactation amenorrhea method; LG-IUS: levonorgestrel-releasing intrauterine system; POC: progestogen-only contraceptive. POI: progestogen-only injectable; POP: progestogen-only pill; PPIUCD: Postpartum intrauterine contraceptive device; NSV: no scalpel vasectomy.

Algorithm – PPCC in non-breastfeding women



CuIUCD: copperIUCD; LG-IUS: Levonorgestrel-releasing intrauterine system; POC: progestogen-only contraceptive. POI: progestogen-only injectable; POP: Progestogen-only pill; PPIUCD: Postpartum Intrauterine Contraceptive Device; NSV: no scalpel vasectomy.

What is lactational amenorrhea method (LAM)?

- Exclusively breastfeeding
- Menses has not returned
- Upto 6 months postpartum
- If any of these three criteria is not met: follow algorithm for breastfeeding women

Advantages of LAM

- Breastfeeding practices required by LAM have other health benefits for mother and baby.
- Bonding protects baby from disease, healthiest food for baby.
- Universally available.
- Can be used immediately after childbirth.

Emergency contraception (irrespective of breastfeeding status)


- Within 72 hrs of unprotected sexual intercourse (UPSI): Levonorgestrel (LNG) 1.5 mg single dose (after 3 weeks postpartum).
- Within 5 days of UPSI:

1) Copper intrauterine device (Cu IUD)/levonorgestrel-releasing intrauterine system (LNG-IUS) (after 4 weeks postpartum)

2) Ulipristal acetate 30mg (after 3 weeks postpartum)

Avoid breastfeeding for 1 week within 5 days of UPSI

• Within 5 days > 3 weeks of birth of UPSI: Ulipristal acetate 30 mg




*Avoid breastfeeding for 1 week and discard milk


Cu IUD: Copper intrauterine device; LNG-IUS: levonorgestrel-releasing intrauterine system; UPA: ulipristal acetate; UPSI: unprotected sexual intercourse

Comparing typical effectiveness of contraceptive methods

More effective



School of Public Health/Center for Communication Programs (CCP). Knowledge for health project. Family planning: a global handbook for providers (2011 update). Baltimore, MD; Geneva, Switzerland: CCP and WHO; 2011; and Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.









PREFACE

Preterm labour is the labor that starts before 37 weeks' of gestation. It is an important problem in obstetrics that affects 23% of pregnancies in India. It is considered as one of the most important risk factors for neonatal morbidity and mortality.

Preterm labour is a multifactorial problem and it's most common causes include ascending infection, multiple gestations, polyhydramnios, and uterine developmental malformations. Although the improved ability of obstetric care providers to identify pregnant women at risk for preterm delivery has increased, the overall incidence of preterm birth has remained unchanged for the past 30 years.

Among the various risk factors such as nutritional status, chronic diseases, and intrauterine malformation contributing to preterm labour, the strongest ones are multiple pregnancies and previous incidence of preterm delivery. In order to identify asymptomatic women at the risk of preterm delivery, cervical length assessment has been recommended to be performed in the second trimester of pregnancy. For a gynaecologist, knowledge of the molecular mechanisms responsible for the process of preterm labour and its early diagnosis is important. With a thorough review of the literature assessing the causes and consequences of preterm labour, FOGSI presents the following algorithm of diagnostic approach and possible preventive measures that provide a framework to improve the outcomes of preterm delivery.

Best wishes!

Nelite P. Palshetkor

Dr. Nandita Palshetkar

MD, FCPS, FICOG President 2019 - Federation of Obstetrics & Gynecological Societies of India (FOGSI)

PRETERM LABOUR

FOGSI President

: Dr. Nandita Palshetkar

Moderators

Co-ordinators

Panelists

: Dr. Tushar Kar

Dr. Ameya Purandare

- : Dr. Jiteeka Thakkar
 - : Dr. Pratik Tambe, Dr. Vaishali Chavan, Dr. Selvapriya S, Dr. Sareena Gilvaz, Dr. Jeyarani Kamaraj, Dr. Ambujam K, Dr. Joshy Joseph N



From left to right: *Standing* – Standing - Dr. Joshy Joseph N, Dr. Vaishali Chavan, Dr. Pratik Tambe, Dr. Ambujam K, Dr. Nandita Palshetkar, Dr. Tushar Kar, Dr. Jeyarani Kamraj, Dr. Ameya Purandare, *Sitting* – Dr. Sareena Gilvaz, Dr. Jiteeka Thakkar, Dr. Selvapriya

Background, scope, and extent


- Prevalence of preterm labour in India is 23.3%.¹
- Over 35,00,000 annual preterm births in India.²
- Highest incidence in the world.

Definition of diagnosed, threatened and established preterm labour


• Preterm is defined as babies born alive before 37 weeks of pregnancy are completed.³

Subcategory

- Extremely preterm: Less than 28 weeks.
- Very preterm: 28–32 weeks.
- Late preterm: 32–37 weeks.
- Suspected/threatened preterm labour: Uterine contractions without cervical dilatation.
- Diagnosed preterm labour: Uterine contractions with cervical changes.
- Established preterm labour: Uterine contractions plus progressive cervical dilatation more than 4 cm.⁴



Algorithm for further management



TVCL: Transvaginal cervical length; TACL: Transabdominal cervical length; CL: Cervical length; PPROM: Preterm premature rupture of the membranes.

Definition of preterm labour

• Defined as labour after 24 weeks gestation and before 37 weeks gestation.⁵

Recommendation: In Indian context

- Labour between 20 and 37 weeks of gestation.
- Medical Termination of Pregnancy Act covers abortion upto 20 weeks,⁶ whereas in the UK, cut-off is 24 weeks.


Screening

History	Modifiable risk factors		
History	Non-modifiable risk factors		
Based on cervical length	Ultrasonography for cervical length		
Per speculum examination/vaginal examination	Screening for vaginal infections and bacterial vaginosis		

Risk factors for spontaneous preterm birth

Modifiable risk factors for spontaneous preterm birth ⁷						
Cigarette smoking						
 Illicit drug use Anemia Bacteriuria/urinary tract infection Gingival disease 	Lower genital tract infections (including bacterial vaginosis, <i>Neisseria gonorrhoea</i> , <i>Chlamydia trachomatis</i> , Group B <i>Streptococcus, Ureaplasma urealyticum</i> , and <i>Trichomonas vaginalis</i>)					
Strenuous work/work environment						
Non-modifiable risk factors for spontaneous preterm birth ⁷						
 Prior preterm birth Age <18 years or >40 years Poor nutrition Low prepregnancy weight Low socioeconomic status Absent prenatal care 	 Cervical injury or anomaly Uterine anomaly Excessive uterine activity (?) Premature cervical dilatation (<2 cm) or effacement (> 80%) Overdistended uterus (twins, polyhydramnios) Vaginal bleeding 					

Screening and prevention strategies



TACL: Transabdominal cervical length.

Utility of prevention strategies

Strategies that have limited or no proven efficacy

- Bed rest
- Pelvic rest (avoidance of intercourse)
- Intensive education and prenatal care
- Screening and treatment of asymptomatic lower genital tract infections
- Treatment of gingival disease
- Empirical broad-spectrum antibiotic therapy

Strategies that may have some benefit

- · Prevention and early diagnosis of sexually transmitted and genitourinary infections
- Treatment of symptomatic lower genital tract infection
- Cessation of smoking and illicit substance use
- Prevention of multiple pregnancies
- Elective (prophylactic) cervical cerclage, if indicated
- Folic acid supplementation

Referral for cervical length screening

Women with a singleton pregnancy who can be offered referral for a single cervical length between 16–24 weeks gestation are:⁸

- Women with a history of mid-trimester loss or preterm birth between 16–34 weeks gestation.
- Women with a history of preterm prelabour rupture of membranes in a previous pregnancy.
- Women with a previous large loop excision of the transformation zone (LLETZ) of >10mm depth.

Who to offer screening

- Low risk population Suggested (as a part of Universal Screening)
- High risk population
 Recommended

When to offer screening

RCOG recommends 16-24 weeks.⁵

However, in high-risk populations it can be performed during the first trimester anomaly scan.

Universal cut-off for cervical length

- Transvaginal route: Recommended
- Cervical length: ≤ 25 mm⁹

Outcome of screening

 If an ultrasound shows a cervical length <25 mm the woman should have a discussion with her consultant about the risks and benefits of vaginal progesterone, cervical cerclage, or expectant management.¹⁰

Other screening tests

- Litmus paper test/nitrazine paper test
- Fetal fibronectin (fFN) levels^{11,12}

fFN Level	N (%)	≤ 7 days	≤ 14 days	≤ 34 days
< 10 ng/ml	170 (57%)	1%	1.8%	1.5%
11–49 ng/ml	62 (21%)	0%	1.6%	8.2%
50–199 ng/ml	41 (14%)	0%	7.7%	11.5%
200–499 ng/ml	14 (5%)	14%	29%	33%
≥500 ng/ml	13 (4%)	38%	46%	75%

Fetal fibronectin levels

- Negative predictive value is excellent.
- Negative test implies negligible risk of preterm birth in next 7 days.
- Positive predictive values is equally good and levels > 200 should be used as a cut off for antenatal corticosteroids and in utero transfer.

Role of tocolysis¹³

- Administer corticosteroids to enhance pulmonary maturity.
- Reduce the severity of fetal respiratory distress syndrome.
- To reduce the risk of intraventricular hemorrhage.
- Facilitate transfer of the patient to a tertiary care center with NICU facilities.

Isoxsuprine

- First-line therapy according to American College of Obstetricians and Gynecologists (ACOG) recommendations.¹⁴
- Central Drugs Standard Control Organisation (CDSCO) approved drug in PTL.¹⁴
- IV infusion 4 ampoules in 500 ml 5% dextrose/RL.
- Start with 08–10 drops per min, increase 8 drops every 15 min till the uterus become quiet.
- Maximum dose should not exceed more than 40 drops.
- Monitor the BP.
- Dose can be titrated as per the response of the patient.

I	M injections	Oral
•	Administered at the onset of	• Oral administration of isoxsuprine should
	premature labour, only if facilities for	be subsequent to IV or IM administration
	IV administration are not available and	provided uterine activity has completely
	continued until control is obtained on	subsided
	symptoms of preterm labour	• 60 to 80 mg daily in divided doses is the
•	Dose is 10 mg every 1–2 hours	usual maintenance dose

Maintenance therapy of isoxsuprine hydrochloride

• Indian evidence suggests that isoxsuprine is superior with regards to maternal and fetal outcome when administered in appropriate doses.¹

Evidence 1

 Jaju et al (Dec 2017), in a recently concluded study in Indian patients, reported that patients receiving oral dose of isoxsuprine with a maximum daily dose of up to 40 mg for an average of 23 days had a mean latency period of 37 days. Significant improvement in prolongation of delivery beyond 48 hours and perinatal outcomes were also noted amongst these patients on isoxsuprine versus other pharmacological agents.¹⁴

Evidence 2

 In study reported by V.K. Singh et al, isoxsuprine was initially administered intravenously, which was followed by maintenance oral therapy till 37 weeks of gestation. In this study, the mean latency period reported was 28 days, maximum being 70 days.¹

Evidence 3

- Efficacy and safety of isoxsuprine hydrochloride as uterine relaxant in preterm labor -A prospective, open-label, non-comparative study- 2018 [presented as a poster in COGI (The Multidisciplinary Gynecology Congress, Controversies in Obstetrics, Gynecology & Infertility), London] isoxsuprine hydrochloride was continued till delivery/37 weeks of gestation.¹⁶
- Total latency period was 58.5±18.5 days.


Evidence 4

- Comparison of isoxsuprine 10 mg and 40 mg for the management of preterm mothers: A prospective study.
- According to Dr. M Kavitha et al, the mean duration of prolongation of pregnancy in 10 mg group was 4 days and in 40 mg group was 15 days.¹

Recent studies

Recent Indian studies have shown encouraging results when it was used in maintenance after the arrest of preterm labour, however clinician should decide the duration of therapy based on patients response.

Atosiban



Off label drugs used in the management of PTL

Some of the off label drugs used in preterm in India includes nifedipine, indomethacin, nitric oxide donors. Even though Western guidelines mentioned these agents in management of preterm labour in India, CDSCO has not approved its usage.

Neuroprotective agents

Magnesium sulphate

- Confers neuroprotection to the neonate and is used for this benefit.
- Offer intravenous magnesium sulphate for neuroprotection of the baby to women between 24+0 and 29+6 weeks of pregnancy who are:⁴
 - » in established preterm labour or
 - » having a planned preterm birth within 24 hours.

Dosage regime¹⁸

- A loading dose of 4 g (8 ml of 50% magnesium sulphate), diluted with 12 ml of saline 0.9% (total 20 ml), is given IV over 5–10 minutes using a 20 ml syringe.
- A maintenance dose of 10 g (20 ml magnesium sulphate), diluted with 30 ml of saline 0.9% (total 50 ml) is set up to deliver 1 gram per hour (5 ml/hr) using a syringe driver, until delivery.
- If delivery is imminent it is appropriate to give only the loading dose.
- For a planned lower segment Caesarean section delivery start the regime 4 hours prior to expected delivery time.

Role of prophylactic cervical cerclage

- Consider prophylactic cervical cerclage for women in whom a transvaginal ultrasound scan has been carried out between 16–24 weeks of pregnancy that reveals a cervical length of less than 25 mm and who have either:⁴
 - » Had preterm prelabour rupture of membranes in a previous pregnancy or
 - » A history of cervical trauma.

Progesterone

- Indications: Short cervix on transvaginal ultrasound.
- 17-OH-progesterone 250 mg IM once weekly is recommended in high-risk preterm labour.⁷

Maternal antenatal corticosteroids

- For women between 23+0 and 23+6 weeks of pregnancy who are in suspected or established preterm labour, are having a planned preterm birth or have PPROM discuss with the woman (and her family members or carers as appropriate) the use of maternal corticosteroids in the context of her individual circumstances.⁴
- Consider maternal antenatal corticosteroids 24+0 and 25+6 weeks of pregnancy who are in suspected or established, or having a planned preterm birth or have PPROM.
- Offer maternal antenatal corticosteroids 26+0 and 33+6 weeks of pregnancy who are in suspected or established preterm labour, are having a planned preterm birth or have PPROM.⁴

Choice of agent

- Dexamethasone or betamethasone either can be used.
- Dosages : Dexamethasone/Betamethasone 12mg IM, two doses, 24 hours apart should be administered.¹⁹
- Do not routinely offer repeat courses of maternal corticosteroids, but take into account:
 - » The interval since the end of last course
 - » Gestational age
 - » The likelihood of birth within 48 hours.

Antibiotics in preterm labour/PPROM Should antibiotics be given?

Recommendation	Evidence Quality	Strength	Notes
Erythromycin should be given to 10 days following the diagnosis PPROM, or until the woman is in established labour (whichever is sooner)	1+	A	A Cochrane review found benefits when antibiotics administered: reduced chorioamnionitis, prolonged latency, and improved neonatal outcomes. ²⁰

- Ideal agent is penicillin if patient is allergic to erythromycin
- Co-amoxiclav is not recommended owing to its association with NEC

When do we plan delivery?

When is the appropriate time to deliver the baby?

Recommendation	Evidence Quality	Strength	Notes
Women in whom pregnancy is complicated by PPROM and who have no contraindications to continuing the pregnancy should be offered expectant management coma as this is associated with better outcomes compared with early birth	1+	A	A cochrane review found clear benefits from expectant management, rather than early delivery, following PPROM ²¹
Early delivery may be preferable when PPROM occurs beyond 34+0 weeks of of gestation in women known to be colonized with group B streptococcus	4	D	RCOG Green-top Guideline No. 36.29 ²

RCOG: Royal College of Obstetricians and Gynaecologists; PPROM: Preterm premature rupture of the membranes.

Which is the preferred route of delivery?

• Discuss the general benefits and risks of caesarean section and vaginal birth with women in suspected, diagnosed or established preterm labour and women with P-PROM (and their family members or carers as appropriate).

What are the options if there is a malpresentation?

• Consider caesarean section for women presenting in suspected, diagnosed or established preterm labour between 26+0 and 36+6 weeks of pregnancy with breech presentation.

How do we monitor the fetus in labour? Discuss with the woman

- The purpose of fetal monitoring and what it involves.
- The clinical decisions it informs at different gestational ages.
- Continuous FHR monitoring should ideally be performed.

Delivery considerations

- Aim for atraumatic delivery
- Avoid ventouse
- Obstetric forceps if indicated
- Neonatologist present
- Early transfer to NICU after stabilization

Are there any specific do's and don'ts for cord clamping?

If a preterm baby needs to be moved away from the mother for resuscitation, or there is significant maternal bleeding:

- Consider milking the cord.
- Clamp the cord as soon as possible.
- Wait at least 30 seconds, but no longer than 3 minutes, before clamping the cord of preterm babies, if the mother and baby are stable.
- Position the baby at or below the level of the placenta before clamping the cord.
- Keep the cord length long for subsequent access.

Conclusion

- Preterm labor is an improtant factor for neonatal morbidity and mortality.
- Early screening should be done to prevent preterm labour.
- Antenatal corticosteroids are recomended to reduce neonatal morbidity and mortality.
- Tocolytics have been found to be useful in delaying preterm labour.
- Only Isoxsuprine and Atosiban are approved by CDSCO in the management of pretem labour, however in Indian context isoxsuprine should be considered as it is economical and proven to be efficacious.
- Beta-adrenergic receptor agonists, isoxsuprine, has been approved by Drug Controller General of India (DCGI) for use in preterm labor in Indian women recent studies have shown its benefit in maintenance, however clinician should decide it based on the response of the patient.

- Magnesium sulphate should be used as neuroprotective.
- Erythromycin should be given for 10 days following the diagnosis PPROM, or until the woman is in established labour (whichever is sooner).

References

- 1. Jamal S, Srivastava R. A retrospective analytical study of the epidemiology and causes of preterm birth. Int J Reprod Contracept Obstet Gynecol. 2017 Dec;6(12):5453–457.
- 2. https://www.nhp.gov.in/disease/reproductive-system/female-gynaecological-diseases-/preterm-birth
- 3. WHO. Preterm labour https://www.who.int/news-room/fact-sheets/detail/preterm-birth
- 4. NICE Guideline, No. 25. Preterm Labour and Birth. National Collaborating Centre for Women's and Children's Health (UK). London: National Institute for Health and Care Excellence (UK); 2015 Nov.
- 5. Royal College of Obstetricians & Gynaecologists. Green-top Guideline: Care of women presenting with suspected preterm prelabour rupture of membranes. https://www.rcog.org.uk/globalassests/documents/guidelines/consultation-documents/ preterm-rupture-of-membranes-draft-peer-review.pdf
- 6. Phanjoubam M. Proposed amendments in the Medical Termination of Pregnancy Act in a nutshell. J Med Soc 2017;31:1–2.
- 7. Norwitz ER, Phaneuf LE, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol. 2011 Summer; 4(2): 60–72.
- 8. Care AG, Sharp AN, Lane S, et al. Predicting preterm birth in women with previous preterm birth and cervical length ≥ 25 mm. Ultrasound Obstet Gynecol 2014; 43: 681–86.
- 9. FIGO working Group on best practice in Maternal-Fetal Medicine. FIGO committee report: Best practice in maternal-fetal medicine. International Journal of Gynecology and Obstetrics. 2015; 128:80–82.
- 10. Lee HJ, Park TC, Norwitz ER, et al. Management of pregnancies with cervical shortening: A very short cervix is a very big problem. Rev Obstet Gynecol. 2009 Spring; 2(2): 107–15.
- 11. Abbott DS, Radford SK, Seed PT, et al. Evaluation of a quantitative fetal fi bronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2012; 208.
- 12. Data from file: Rapid fFN® 10Q Cassette Kit
- 13. Spencer C, Neales K. Antenatal corticosteroids to prevent neonatal respiratory distress syndrome. We do not know whether repeated doses are better than a single dose. BMJ. 2000;320(7231):325–26.
- 14. Jaju PB, Chavan V, Devgarha G, et al. Practice patterns in the management of preterm labor in India: A multicentric, retrospective study. Int J Reprod Contracept Obstet Gynecol. 2017; 6(12):5306–312.
- 15. Singh N, Singh U, Seth S. Comparative study of nifedipine and isoxsuprine as tocolytics for preterm labor. The Journal of Obstetrics and Gynecology of India. 2011;61:512–15.
- Jaju PB. Efficacy and safety of isoxsuprine hydrochloride as uterine relaxant in preterm labor A prospective, open-label, non-comparative study (First analysis results), India. OP1-305. The 26th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) COGI London, UK. November 23-25, 2018
- 17. Kavitha M, Malarvizhi KL, Anuradha S, Padmanaban S. Comparison of isoxsuprine 10 mg and 40 mg for the management of preterm mothers: A prospective study. International Journal of Clinical Obstetrics and Gynaecology. 2018; 2(4): 13-17.
- 18. RCOG. Magnesium sulphate to prevent cerebral palsy following preterm birth. Scientific Impact Paper No. 29 August 2011
- 19. WHO. WHO recommendation on use of either dexamethasone or betamethasone as the antenatal corticosteroid of choice. 17 November 2015 https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/ pregnancy-complications/preterm-birth/who-recommendation-use-either-dexamethasone-or-betamethasone-antenatal-corticosteroid-choice
- 20. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes.Cochrane Database of Systematic Reviews2013, Issue 12. Art. No.: CD001058.DOI: 10.1002/14651858.CD001058.pub3.
- 21. Bond DM, Middleton P, Levett KM, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Syst Rev. 2017 Mar 3;3:CD004735.
- 22. Hughes RG, Brocklehurst P, Steer PJ, Heath P, Stenson BM on behalf of the Royal College of Obstetricians and Gynaecologists. Prevention of early-onset neonatal group B streptococcal disease. Green-top GuidelineNo. 36. BJOG 2017;124:e280– e305.